In this study we see Ldopa administered concurrent with a decarboxylase inhibitor decreased Prolactin levels.
It also shows that in order for Ldopa to effectively reduce prolactin metabolism MUST happen in the brain.
This means that other supplements currently available which claim to inhibit prolactin DO NOT WORK.
Why? Because they contain vitb6 or P5P which increases metabolism outside the blood brain barrier rendering the supplement inactive.
In contrast, Prolactrone contains a strong decarboxylase inhibitor which prevents metabolism outside the blood brain barrier making Prolactrone the ONLY effective prolactin reducing supplement on the market...period.
Highlight 1. Ldopa suppresses prolactin.
2. The addition of carbidopa (a decarboxylase inhibitor similar to that which is in Prolactrone) further enhances the prolactin reducing effect.
3. Ldopa acts predominantly through the formation of dopamine in the hypothalamus, but inside the blood-brain barrier which requires the concurrent administration of a decarboxylase inhibitor.
Neurology. 1981 Oct;31(10):1356-9.
Prolactin secretion in Parkinson disease.
Eisler T, Thorner MO, MacLeod RM, Kaiser DL, Calne DB.
We studied the dopaminergic control of lactotroph cells in the anterior pituitary of parkinsonian patients and age-matched normal subjects. The resting levels of prolactin and the TRH-induced rise in prolactin were normal in Parkinson disease. 1. --Levodopa elicited a normal suppression of prolactin concentrations in parkinsonian subjects; the major abnormality to emerge was attenuation of the response to thyrotropin-releasing hormone (TRH) in the parkinsonian patients following administration of Sinemet (levodopa plus carbidopa) or bromocriptine. These findings imply pathology of extrastriatal dopamine systems in Parkinson disease. 2. Since the addition of carbidopa enhanced the suppression of prolactin induced by levodopa, exogenous levodopa probably 3. acts predominantly through the formation of dopamine in the hypothalamus, but inside the blood-brain barrier, rather than as a direct effect of circulating dopamine on the anterior pituitary or areas of the hypothalamus outside the blood-brain barrier.
[PubMed - indexed for MEDLINE]